• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Provention Bio, Inc. - Common Stock (NQ:PRVB)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 24.97 (100)
Ask (Size) 25.05 (8)
Prev. Close 24.98
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 94,780,874
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company? ↗
June 15, 2023
Company Moves Ahead With Drug Development 
Via Benzinga
Provention Bio Inc. (NASDAQ: PRVB) Highlighted for Surprising Price Action
April 26, 2023
Via Investor Brand Network

Performance

More News

Read More
News headline image
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗
April 19, 2023
Via Benzinga
News headline image
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise ↗
April 12, 2023
Via Benzinga
News headline image
Is Sanofi Stock a Buy Now? ↗
March 25, 2023
Via The Motley Fool
News headline image
Provention Bio's Earnings Outlook ↗
March 15, 2023
Via Benzinga
News headline image
4 Analysts Have This to Say About Provention Bio ↗
March 14, 2023
Via Benzinga
Provention Bio, Inc. (NASDAQ: PRVB) Making Surprising Moves in Monday Session
March 13, 2023
Via Investor Brand Network
News headline image
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information ↗
April 11, 2023
Via Benzinga
News headline image
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
March 29, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 23, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That May Crash In March ↗
March 22, 2023
Via Benzinga
News headline image
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗
March 17, 2023
Via Investor's Business Daily
News headline image
Why Provention Bio Stock Skyrocketed 256% This Week ↗
March 16, 2023
Via The Motley Fool
News headline image
Why Shares of MacroGenics Climbed Thursday ↗
March 16, 2023
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023 ↗
March 15, 2023
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗
March 14, 2023
Via Benzinga
News headline image
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗
March 14, 2023
Via Benzinga
News headline image
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
March 13, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners ↗
March 13, 2023
Via The Motley Fool
News headline image
Nasdaq Up 150 Points; Gold Rises Over 2% ↗
March 13, 2023
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 13, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
March 13, 2023
Via Spotlight Growth
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
March 13, 2023
Via Benzinga
News headline image
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
March 13, 2023
Via Benzinga

Frequently Asked Questions

Is Provention Bio, Inc. - Common Stock publicly traded?
Yes, Provention Bio, Inc. - Common Stock is publicly traded.
What exchange does Provention Bio, Inc. - Common Stock trade on?
Provention Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Provention Bio, Inc. - Common Stock?
The ticker symbol for Provention Bio, Inc. - Common Stock is PRVB on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap